Trial Profile
VINORELBINE AND CAPECITABINE as first line treatment in advanced breast cancer patients with non measurable lesions for RECIST criteria.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 May 2011
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 26 May 2011 New trial record